Flagship Ventures to back Red Rock Biofuels

Flagship Ventures has agreed to invest in Red Rock BioFuels LLC. No financial terms were disclosed. Also, Flagship Ventures will take a seat on Red Rock’s board of directors. Based in Fort Collins, Colorado, Red Rock Biofuels is a provider of renewable biofuels.


Blend Therapeutics scores $21 mln

Watertown, Mass.-based Blend Therapeutics, a biopharmaceutical firm focused on treating cancer, has raised $21 million in funding. Blend’s investors include New Enterprise Associates, Flagship Ventures, NanoDimension and Eminent Venture Capital.

VC-backed Acceleron Pharma adds to board of directors

Acceleron Pharma has appointed Dr. Francois Nader to its board of directors. Nader is president, CEO and a member of the board of directors of NPS Pharma. Acceleron Pharma’s backers include Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures and Venrock. Based in Cambridge, Mass., Acceleron is focused on developing novel protein therapeutics for cancer and rare diseases.

Seres Health fetches $48 mln

Seres Health has raised $48 million in Series C funding. The investors in this round were not named; however, the firm was seeded by Flagship Ventures. Based in Cambridge, Mass., Seres Health is a biotherapeutic company focused on developing drugs that target the human microbiome.


Flagship Ventures backs Symbiota

Symbiota has closed $7.5 million in Series A funding from Flagship Ventures. Based in Cambridge, Mass., Symbiota is a provider of microbial solutions.


Selecta Biosciences raises $20 million

Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.


Visterra closes $30 mln Series B

Biotechnology company Visterra has completed a $30 million Series B financing round. The round was co-led by new Visterra investors Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek. Existing investors Polaris Partners, Flagship Ventures, Omega Funds and Alexandria Venture Investments and a new investor Cycad Group also participated.


Seventh Sense Biosystems raises $16 mln in Series B funding

Seventh Sense Biosystems, which develops blood collection and diagnostic platforms, has raised $16 million in Series B funding from a group of investors. New investors in the funding were the venture capital arm of Siemens Financial Services, Novartis and Laboratory Corporation of America Holdings. Existing investors Flagship Ventures and Polaris Partners also participated in the funding round.

VC-backed Editas Medicine hires CEO

Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund.


MassPRIM’s push into venture slowed last year: VCJ

The Massachusetts Pension Reserves Investment Management’s venture portfolio includes top name funds from Union Square Ventures, Spark Capital and Index Ventures, but after stepping on the gas early this decade, the board’s pace of commitments shifted to a lower gear last year, affiliate magazine Venture Capital Journal reports.

VC-backed Syros Pharmaceuticals hires new CFO

Syros Pharmaceuticals said Tuesday that it has hired Jorge Conde as chief financial officer and chief product officer. Previously, Conde was the co-founder and CFO of Knome. Based in Watertown, Mass., Syros is focused on treating cancer and other diseases. It is backed by Flagship Ventures and ARCH Venture Partners.

Seres Health pulls in $10 mln Series B

Seres Health said Monday that it has received $10 million in Series B funding. The investors included Flagship Ventures, Enso Ventures, Mayo Clinic and Alexandria Venture Investments. Based in Cambridge, Mass., Seres Health is a clinical stage biotherapeutic company focused on developing drugs that target the human microbiome.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget